Journal of endourology · 2026
A Novel Thermally Expanding Nickel-Titanium Alloy Metallic Ureteral Stent for the Management of Ureteral Strictures.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhuo, Liu Shuai, Zhuo Lin, Liu Ke, Hao Yichang, Zhang Hongxian, Zhang Shudong, Xiao Chunlei
Аннотация
BACKGROUND: The management of complex ureteral strictures remains a significant urologic challenge. Although metallic stents offer an alternative to traditional polymer stents, long-term data on their efficacy, particularly for newer devices, are limited. This study evaluates the safety and efficacy of a novel, domestically produced thermally expanding nickel-titanium alloy stent (Fulbright®) in treating various ureteral strictures.
METHODS: A prospective, single-center study was conducted between August 2024 and September 2025. Consecutive patients with ureteral strictures of diverse etiologies (e.g., stone-related, postradiation, iatrogenic, idiopathic) were enrolled. All participants underwent implantation of the thermally expanding nickel-titanium alloy stent (Fulbright). Primary outcomes included technical success, stent patency, and changes in renal function parameters (serum creatinine, estimated glomerular filtration rate (eGFR), hydronephrosis volume) assessed during follow-up.
RESULTS: A total of 21 patients (representing 23 ureteral units) were included. The cohort presented with complex strictures of varied etiology: urolithiasis (39.1%, n = 9), radiation-induced (21.7%, n = 5), iatrogenic (17.4%, n = 4), idiopathic (13.0%, n = 3), and tumor extrinsic compression (8.7%, n = 2). The primary endpoint of an effective decompression was achieved in 87.0% of cases over a median follow-up of 5.0 months (interquartile range [IQR] 2.0-6.0). Postoperative renal function improved significantly, with serum creatinine levels decreasing from a median of 95.0 μmol/L (IQR 73.0-126.0) to 84.0 μmol/L (IQR 68.0-115.0) (p < 0.001). Concurrently, the eGFR increased significantly from 64.8 ± 23.3 mL/min/1.73 m2 to 73.1 ± 22.1 mL/min/w1.73 m2 (p = 0.001). A marked reduction in hydronephrosis volume was also observed, from a median of 57.9 cm³ (IQR 27.7-109.8) to 12.9 cm³ (IQR 5.7-38.4) (p < 0.001). Stent migration was the predominant complication, occurring in 17.4% (4/23) of cases, one of which was effectively managed endoscopically.
CONCLUSIONS: The novel thermally expanding nickel-titanium alloy stent (Fulbright) represents a promising, safe, and effective minimally invasive therapeutic option for managing both benign and malignant ureteral strictures.
METHODS: A prospective, single-center study was conducted between August 2024 and September 2025. Consecutive patients with ureteral strictures of diverse etiologies (e.g., stone-related, postradiation, iatrogenic, idiopathic) were enrolled. All participants underwent implantation of the thermally expanding nickel-titanium alloy stent (Fulbright). Primary outcomes included technical success, stent patency, and changes in renal function parameters (serum creatinine, estimated glomerular filtration rate (eGFR), hydronephrosis volume) assessed during follow-up.
RESULTS: A total of 21 patients (representing 23 ureteral units) were included. The cohort presented with complex strictures of varied etiology: urolithiasis (39.1%, n = 9), radiation-induced (21.7%, n = 5), iatrogenic (17.4%, n = 4), idiopathic (13.0%, n = 3), and tumor extrinsic compression (8.7%, n = 2). The primary endpoint of an effective decompression was achieved in 87.0% of cases over a median follow-up of 5.0 months (interquartile range [IQR] 2.0-6.0). Postoperative renal function improved significantly, with serum creatinine levels decreasing from a median of 95.0 μmol/L (IQR 73.0-126.0) to 84.0 μmol/L (IQR 68.0-115.0) (p < 0.001). Concurrently, the eGFR increased significantly from 64.8 ± 23.3 mL/min/1.73 m2 to 73.1 ± 22.1 mL/min/w1.73 m2 (p = 0.001). A marked reduction in hydronephrosis volume was also observed, from a median of 57.9 cm³ (IQR 27.7-109.8) to 12.9 cm³ (IQR 5.7-38.4) (p < 0.001). Stent migration was the predominant complication, occurring in 17.4% (4/23) of cases, one of which was effectively managed endoscopically.
CONCLUSIONS: The novel thermally expanding nickel-titanium alloy stent (Fulbright) represents a promising, safe, and effective minimally invasive therapeutic option for managing both benign and malignant ureteral strictures.